Tremelimumab
Fab fragment of tremelimumab (blue) binding CTLA-4 (green). From PDB entry 5GGV. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CTLA-4 |
| Clinical data | |
| Trade names | Imjudo |
| Other names | tremelimumab-actl, ticilimumab, CP-675, CP-675,206 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622078 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6500H9974N1726O2026S52 |
| Molar mass | 146382.47 g·mol−1 |
| (what is this?) (verify) | |
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer).[7][8] Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).[8]
The most common side effects when used in combination with durvalumab include rash, pruritus (itching), diarrhea, abdominal (belly) pain, increased levels of liver enzymes, fever, hypothyroidism (an underactive thyroid gland), cough, peripheral edema (swelling especially of the ankles and feet) and increased level of lipase (an enzyme that helps digest fat, mainly made in the pancreas).[8]
Tremelimumab was approved for medical use in the United States in October 2022,[7][9][10] and in the European Union in February 2023.[8]
- ^ "Imjudo". Therapeutic Goods Administration (TGA). 29 June 2023. Retrieved 10 September 2023.
- ^ "Imjudo (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 11 September 2023. Retrieved 10 September 2023.
- ^ "AusPAR: Imjudo". www.tga.gov.au.
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-10-26]". Health Canada. 26 October 2023. Archived from the original on 3 January 2024. Retrieved 3 January 2024.
- ^ "Summary Basis of Decision (SBD) for Imjudo". Health Canada. 3 January 2024. Archived from the original on 17 January 2024. Retrieved 17 January 2024.
- ^ "Details for: Imjudo". Health Canada. 23 October 2023. Archived from the original on 17 January 2024. Retrieved 17 January 2024.
- ^ a b c "Imjudo- tremelimumab injection, solution". DailyMed. 10 November 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.
- ^ a b c d e "Imjudo EPAR". European Medicines Agency (EMA). 9 December 2022. Archived from the original on 3 March 2023. Retrieved 2 March 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Drug Approval Package: Imjudo". U.S. Food and Drug Administration (FDA). 4 November 2022. Archived from the original on 3 March 2023. Retrieved 2 March 2023.
- ^ "Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer". AstraZeneca (Press release). 26 October 2022. Archived from the original on 24 October 2022. Retrieved 26 October 2022.